Pharvaris is a clinical-stage biopharma company focused on discovering and developing novel oral bradykinin B2-receptor antagonists for hereditary angioedema (HAE) and related indications. The company's lead candidate is PHVS416 (PHA121 in soft capsules), a potent orally available B2-receptor antagonist designed to block bradykinin during HAE attacks. Pharvaris is advancing both on-demand treatment and an orally available extended-release formulation intended for prophylactic prevention in HAE patients. Initiation of RAPIDe-1, a multicenter Phase 2 placebo-controlled on-demand study of PHVS416 in HAE patients, was expected in 2021. The company is led by CEO Berndt Modig and is based in Zug, Switzerland. Recent financing activity has strengthened its balance sheet to support clinical advancement of its pipeline.

Total raised

$80M

Funding rounds

1

Latest round

Series C

Latest activity

Nov 2020